Valacyclovir: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 21: | Line 21: | ||
'''| [[Valacyclovir clinical studies|Clinical Studies]]''' | '''| [[Valacyclovir clinical studies|Clinical Studies]]''' | ||
'''| [[Valacyclovir dosage and administration|Dosage and Administration]]''' | '''| [[Valacyclovir dosage and administration|Dosage and Administration]]''' | ||
'''| [[Valacyclovir how supplied|How Supplied]]''' | '''| [[Valacyclovir how supplied|How Supplied]]''' | ||
'''| [[Valacyclovir labels and packages|Labels and Packages]]''' | '''| [[Valacyclovir labels and packages|Labels and Packages]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Revision as of 21:08, 30 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Valaciclovir (INN) or valacyclovir (USAN) is an antiviral drug used in the management of herpes simplex, herpes zoster (shingles), and herpes B. It is a prodrug, being converted [in vivo] error: {{lang}}: text has italic markup (help) to aciclovir. It is marketed by GlaxoSmithKline under the trade names Valtrex and Zelitrex. Valaciclovir has been available as a generic drug in the U.S. since November 25, 2009.[1]
Category
Antiviral
US Brand Names
Valtrex® (Zelitrex)
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
References
- ↑ Ahmed, Rumman (2009-11-27). "Ranbaxy Launches Generic Valtrex in U.S." The Wall Street Journal. Retrieved 2010-01-16.